{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:09:54Z","timestamp":1793941794256,"version":"4.8.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001588","name":"Enterprise Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001592","name":"Higher Education Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Circulating tumour cells (CTCs) are rare yet crucial biomarkers with significant prognostic potential across different cancer types. However, their role in high-grade serous ovarian cancer (HSGC) is not well defined. To capture the full spectrum of CTCs found in HGSC, we employed an EpCAM independent enrichment technique in patients with advanced HGSC and investigated the prognostic value and molecular signatures of these rare cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>CTC enumeration was performed in 43 newly diagnosed patients with HGSC using Parsortix\u00ae CTC enrichment and benchmarked against a metastatic breast cancer (MBC) cohort for which the device is FDA approved. CTCs were also isolated from the ovarian vein of patients with HGSC during primary cytoreductive surgery. CTCs were assessed as prognostic markers in patients with HGSC. FACS single cell sorting and scRNAseq was performed on CTCs isolated from the ovarian vein.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CTCs isolated using Parsortix\u00ae enrichment in HGSC ranged between 1-22 cells\/7.5\u2009ml blood. Concordance was seen between Parsortix\u00ae enrichment and CellSearch\u00ae enumeration in patients with MBC (R\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.8786). CTC clusters were isolated from the ovarian vein (\n                      <jats:italic>P\u2009<\/jats:italic>\n                      =\u20090.0195) and were cloaked in platelets\/immune cells. Detection of CTCs in patients with HGSC was predictive of a poorer progression free survival (\n                      <jats:italic>P\u2009<\/jats:italic>\n                      =\u20090.0183). Patients with CTCs were found to have increased serum levels of CD73 (\n                      <jats:italic>P\u2009<\/jats:italic>\n                      =\u20090.0311). scRNAseq of CTCs isolated from the ovarian vein identified enrichment in genes associated with immune signalling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Peripheral CTCs isolated from patients with HGSC were predictors of a poor prognosis. The ovarian vein was found to be a rich source of disseminating CTC clusters in HGSC. Further studies are warranted to investigate the utility of CTCs as markers of neoadjuvant chemotherapy response as well as for longitudinal monitoring. Molecular analysis of CTCs in HGSCs reveals a potential role of the immune system in CTC-mediated haematogenous metastasis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03227-7","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:28:55Z","timestamp":1761128935000},"page":"22-32","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Circulating tumour cells are a prognostic indicator in advanced high-grade serous ovarian cancer and are associated with platelets and immune cells following dissemination"],"prefix":"10.1038","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9356-7246","authenticated-orcid":false,"given":"Mark P.","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faye","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"O\u2019Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy A.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Lochrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9107-6240","authenticated-orcid":false,"given":"Laura E.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya E.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashir M.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashitha","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roisin","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Kilgour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Kanjuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Hurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Edgerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Gately","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-8262","authenticated-orcid":false,"given":"Lorraine","family":"O\u2019Driscoll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Hokamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Cashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9098-3626","authenticated-orcid":false,"given":"Doug A.","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Selemidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waseem","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Beirne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feras","family":"Abu Saadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Cadoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara M.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"O\u2019Leary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon A.","family":"O\u2019Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"3227_CR1","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/onc.2015.192","volume":"35","author":"K Pantel","year":"2016","unstructured":"Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2016;35:1216\u201324.","journal-title":"Oncogene"},{"key":"3227_CR2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1470-2045(08)70340-1","volume":"10","author":"HI Scher","year":"2009","unstructured":"Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10:233\u20139.","journal-title":"Lancet Oncol"},{"key":"3227_CR3","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1158\/1078-0432.CCR-05-2821","volume":"12","author":"DF Hayes","year":"2006","unstructured":"Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12:4218\u201324.","journal-title":"Clin Cancer Res"},{"key":"3227_CR4","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","volume":"26","author":"SJ Cohen","year":"2008","unstructured":"Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:3213\u201321.","journal-title":"J Clin Oncol"},{"key":"3227_CR5","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.3390\/cancers14092230","volume":"14","author":"J Huang","year":"2022","unstructured":"Huang J, Chan WC, Ngai CH, Lok V, Zhang L, Lucero-Prisno DE 3rd, et al. Worldwide burden, risk factors, and temporal trends of ovarian cancer: a global study. Cancers. 2022;14:2230.","journal-title":"Cancers"},{"key":"3227_CR6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41568-022-00503-z","volume":"22","author":"LE Kandalaft","year":"2022","unstructured":"Kandalaft LE, Dangaj Laniti D, Coukos G. Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. Nat Rev Cancer. 2022;22:640\u201356.","journal-title":"Nat Rev Cancer"},{"key":"3227_CR7","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(23)00335-2","volume":"24","author":"U Menon","year":"2023","unstructured":"Menon U, Gentry-Maharaj A, Burnell M, Ryan A, Singh N, Manchanda R, et al. Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial. Lancet Oncol. 2023;24:1018\u201328.","journal-title":"Lancet Oncol"},{"key":"3227_CR8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/IGC.0000000000000316","volume":"25","author":"A Pereira","year":"2015","unstructured":"Pereira A, Perez-Medina T, Magrina JF, Magtibay PM, Rodriguez-Tapia A, Peregrin I, et al. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer. Int J Gynecol Cancer. 2015;25:49\u201354.","journal-title":"Int J Gynecol Cancer"},{"key":"3227_CR9","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-00933-8","volume":"22","author":"RD Mahmood","year":"2020","unstructured":"Mahmood RD, Morgan RD, Edmondson RJ, Clamp AR, Jayson GC. First-line management of advanced high-grade serous ovarian cancer. Curr Oncol Rep. 2020;22:64.","journal-title":"Curr Oncol Rep"},{"key":"3227_CR10","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217279","volume":"605","author":"F Lewis","year":"2024","unstructured":"Lewis F, Beirne J, Henderson B, Norris L, Cadoo K, Kelly T, et al. Unravelling the biological and clinical challenges of circulating tumour cells in epithelial ovarian carcinoma. Cancer Lett. 2024;605:217279.","journal-title":"Cancer Lett"},{"key":"3227_CR11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trsl.2016.03.016","volume":"175","author":"LG Coffman","year":"2016","unstructured":"Coffman LG, Burgos-Ojeda D, Wu R, Cho K, Bai S, Buckanovich RJ. New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination. Transl Res. 2016;175:92\u2013102.e2.","journal-title":"Transl Res"},{"key":"3227_CR12","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.ccell.2024.08.016","volume":"42","author":"E Bayraktar","year":"2024","unstructured":"Bayraktar E, Chen S, Corvigno S, Liu J, Sood AK. Ovarian cancer metastasis: Looking beyond the surface. Cancer Cell. 2024;42:1631\u20136.","journal-title":"Cancer Cell"},{"key":"3227_CR13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1158\/1078-0432.CCR-06-1695","volume":"13","author":"S Riethdorf","year":"2007","unstructured":"Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007;13:920\u20138.","journal-title":"Clin Cancer Res"},{"key":"3227_CR14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ygyno.2021.02.024","volume":"161","author":"C Huang","year":"2021","unstructured":"Huang C, Lin X, He J, Liu N. Enrichment and detection method for the prognostic value of circulating tumor cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2021;161:613\u201320.","journal-title":"Gynecol Oncol"},{"key":"3227_CR15","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ygyno.2011.05.028","volume":"122","author":"A Poveda","year":"2011","unstructured":"Poveda A, Kaye SB, McCormack R, Wang S, Parekh T, Ricci D, et al. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed\/recurrent advanced ovarian cancer. Gynecol Oncol. 2011;122:567\u201372.","journal-title":"Gynecol Oncol"},{"key":"3227_CR16","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04242-z","volume":"21","author":"M Farhang Ghahremani","year":"2023","unstructured":"Farhang Ghahremani M, Seto KKY, Cho W, Miller MC, Smith P, Englert DF. Novel method for highly multiplexed gene expression profiling of circulating tumor cells (CTCs) captured from the blood of women with metastatic breast cancer. J Transl Med. 2023;21:414.","journal-title":"J Transl Med"},{"key":"3227_CR17","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood.2023022928","volume":"144","author":"JB Schaubaecher","year":"2024","unstructured":"Schaubaecher JB, Smiljanov B, Haring F, Steiger K, Wu Z, Ugurluoglu A, et al. Procoagulant platelets promote immune evasion in triple-negative breast cancer. Blood. 2024;144:216\u201326.","journal-title":"Blood"},{"key":"3227_CR18","volume":"20","author":"MP Ward","year":"2021","unstructured":"Ward MP, Kane LE, Norris LA, Mohamed BM, Kelly T, Bates M, et al. Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?. Mol Cancer. 2021;20:59.","journal-title":"Mol Cancer"},{"key":"3227_CR19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576\u201390.","journal-title":"Cancer Cell"},{"key":"3227_CR20","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12094-011-0687-9","volume":"13","author":"V Asher","year":"2011","unstructured":"Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011;13:499\u2013503.","journal-title":"Clin Transl Oncol"},{"key":"3227_CR21","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101229","volume":"14","author":"CD Spillane","year":"2021","unstructured":"Spillane CD, Cooke NM, Ward MP, Kenny D, Blackshields G, Kelly T, et al. The induction of a mesenchymal phenotype by platelet cloaking of cancer cells is a universal phenomenon. Transl Oncol. 2021;14:101229.","journal-title":"Transl Oncol"},{"key":"3227_CR22","doi-asserted-by":"crossref","first-page":"e26125","DOI":"10.1371\/journal.pone.0026125","volume":"6","author":"K Egan","year":"2011","unstructured":"Egan K, Crowley D, Smyth P, O\u2019Toole S, Spillane C, Martin C, et al. Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PLoS One. 2011;6:e26125.","journal-title":"PLoS One"},{"key":"3227_CR23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/thoraxjnl-2019-214027","volume":"75","author":"Z Useckaite","year":"2020","unstructured":"Useckaite Z, Ward MP, Trappe A, Reilly R, Lennon J, Davage H, et al. Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis. Thorax. 2020;75:449\u201358.","journal-title":"Thorax"},{"key":"3227_CR24","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1200\/JCO.2005.08.140","volume":"23","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005;23:1420\u201330.","journal-title":"J Clin Oncol"},{"key":"3227_CR25","volume":"9","author":"T Zhang","year":"2021","unstructured":"Zhang T, Agarwal A, Almquist RG, Runyambo D, Park S, Bronson E, et al. Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer. Biomark Res. 2021;9:14.","journal-title":"Biomark Res"},{"key":"3227_CR26","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.2119\/molmed.2015.00149","volume":"21","author":"JE Hardingham","year":"2015","unstructured":"Hardingham JE, Grover P, Winter M, Hewett PJ, Price TJ, Thierry B. Detection and clinical significance of circulating tumor cells in colorectal cancer-20 years of progress. Mol Med. 2015;21:S25\u201331.","journal-title":"Mol Med"},{"key":"3227_CR27","volume":"8","author":"L Cui","year":"2015","unstructured":"Cui L, Kwong J, Wang CC. Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis. J Ovarian Res. 2015;8:38.","journal-title":"J Ovarian Res"},{"key":"3227_CR28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ygyno.2014.03.016","volume":"133","author":"N Romero-Laorden","year":"2014","unstructured":"Romero-Laorden N, Olmos D, Fehm T, Garcia-Donas J, Diaz-Padilla I. Circulating and disseminated tumor cells in ovarian cancer: a systematic review. Gynecol Oncol. 2014;133:632\u20139.","journal-title":"Gynecol Oncol"},{"key":"3227_CR29","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.3390\/cancers13246225","volume":"13","author":"DB Asante","year":"2021","unstructured":"Asante DB, Morici M, Mohan G, Acheampong E, Spencer I, Lin W, et al. Multi-marker immunofluorescent staining and PD-L1 detection on circulating tumour cells from ovarian cancer patients. Cancers. 2021;13:6225.","journal-title":"Cancers"},{"key":"3227_CR30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-29416-z","volume":"13","author":"DB Asante","year":"2023","unstructured":"Asante DB, Mohan G, Acheampong E, Ziman M, Calapre L, Meniawy TM, et al. Genetic analysis of heterogeneous subsets of circulating tumour cells from high grade serous ovarian carcinoma patients. Sci Rep. 2023;13:2552.","journal-title":"Sci Rep"},{"key":"3227_CR31","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/jnci\/djy018","volume":"110","author":"FC Bidard","year":"2018","unstructured":"Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, et al. Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J Natl Cancer Inst. 2018;110:560\u20137.","journal-title":"J Natl Cancer Inst"},{"key":"3227_CR32","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1245\/s10434-015-4600-6","volume":"22","author":"C Hall","year":"2015","unstructured":"Hall C, Karhade M, Laubacher B, Anderson A, Kuerer H, DeSynder S, et al. Circulating tumor cells after neoadjuvant chemotherapy in stage I-III triple-negative breast cancer. Ann Surg Oncol. 2015;22:S552\u20138.","journal-title":"Ann Surg Oncol"},{"key":"3227_CR33","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10549-020-05658-7","volume":"181","author":"SA O\u2019Toole","year":"2020","unstructured":"O\u2019Toole SA, Spillane C, Huang Y, Fitzgerald MC, Ffrench B, Mohamed B, et al. Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy. Breast Cancer Res Treat. 2020;181:571\u201380.","journal-title":"Breast Cancer Res Treat"},{"key":"3227_CR34","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/IGC.0000000000000514","volume":"25","author":"M Kleppe","year":"2015","unstructured":"Kleppe M, Kraima AC, Kruitwagen RF, Van Gorp T, Smit NN, van Munsteren JC, et al. Understanding lymphatic drainage pathways of the ovaries to predict sites for sentinel nodes in ovarian cancer. Int J Gynecol Cancer. 2015;25:1405\u201314.","journal-title":"Int J Gynecol Cancer"},{"key":"3227_CR35","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3390\/biom13030428","volume":"13","author":"S Francini","year":"2023","unstructured":"Francini S, Duraes M, Rathat G, Macioce V, Mollevi C, Pages L, et al. Circulating tumor cell detection by liquid biopsy during early-stage endometrial cancer surgery: a pilot study. Biomolecules. 2023;13:428.","journal-title":"Biomolecules"},{"key":"3227_CR36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41568-019-0180-2","volume":"19","author":"L Keller","year":"2019","unstructured":"Keller L, Pantel K. Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nat Rev Cancer. 2019;19:553\u201367.","journal-title":"Nat Rev Cancer"},{"key":"3227_CR37","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","volume":"158","author":"N Aceto","year":"2014","unstructured":"Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110\u201322.","journal-title":"Cell"},{"key":"3227_CR38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.31557\/APJCP.2023.24.2.353","volume":"24","author":"M Houshyari","year":"2023","unstructured":"Houshyari M, Taghizadeh-Hesary F. The metastatic spread of breast cancer accelerates during sleep: how the study design can affect the results. Asian Pac J Cancer Prev. 2023;24:353\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"key":"3227_CR39","volume":"51","author":"F Lewis","year":"2025","unstructured":"Lewis F, Ward MP, Saadeh FA, O\u2019Gorman C, Maguire PJ, Beirne JP, et al. A pilot study evaluating the feasibility of enriching and detecting circulating tumour cells from peripheral and ovarian veins in rare epithelial ovarian carcinomas. Eur J Surg Oncol. 2025;51:109721.","journal-title":"Eur J Surg Oncol"},{"key":"3227_CR40","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41588-025-02205-2","volume":"57","author":"D Gremmelspacher","year":"2025","unstructured":"Gremmelspacher D, Gawron J, Szczerba BM, Jahn K, Castro-Giner F, Kuipers J, et al. Phylogenetic inference reveals clonal heterogeneity in circulating tumor cell clusters. Nat Genet. 2025;57:1357\u201361.","journal-title":"Nat Genet"},{"key":"3227_CR41","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00404-020-05477-7","volume":"301","author":"M Banys-Paluchowski","year":"2020","unstructured":"Banys-Paluchowski M, Fehm T, Neubauer H, Paluchowski P, Krawczyk N, Meier-Stiegen F, et al. Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer. Arch Gynecol Obstet. 2020;301:1027\u201335.","journal-title":"Arch Gynecol Obstet"},{"key":"3227_CR42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ygyno.2013.08.006","volume":"131","author":"JF Liu","year":"2013","unstructured":"Liu JF, Kindelberger D, Doyle C, Lowe A, Barry WT, Matulonis UA. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013;131:352\u20136.","journal-title":"Gynecol Oncol"},{"key":"3227_CR43","volume":"11","author":"J Yang","year":"2021","unstructured":"Yang J, Ma J, Jin Y, Cheng S, Huang S, Zhang N, et al. Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial-mesenchymal transition. Sci Rep. 2021;11:6540.","journal-title":"Sci Rep"},{"key":"3227_CR44","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.3390\/cancers12051111","volume":"12","author":"C Costa","year":"2020","unstructured":"Costa C, Muinelo-Romay L, Cebey-Lopez V, Pereira-Veiga T, Martinez-Pena I, Abreu M, et al. Analysis of a real-world cohort of metastatic breast cancer patients shows circulating tumor cell clusters (CTC-clusters) as predictors of patient outcomes. Cancers. 2020;12:1111.","journal-title":"Cancers"},{"key":"3227_CR45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41416-021-01327-8","volume":"125","author":"I Krol","year":"2021","unstructured":"Krol I, Schwab FD, Carbone R, Ritter M, Picocci S, De Marni ML, et al. Detection of clustered circulating tumour cells in early breast cancer. Br J Cancer. 2021;125:23\u20137.","journal-title":"Br J Cancer"},{"key":"3227_CR46","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cell.2018.11.046","volume":"176","author":"S Gkountela","year":"2019","unstructured":"Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, Scherrer R, et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 2019;176:98\u2013112.e14.","journal-title":"Cell"},{"key":"3227_CR47","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.thromres.2021.01.012","volume":"200","author":"MP Ward","year":"2021","unstructured":"Ward MP, Saadeh FA, O\u2019Toole SA, O\u2019Leary JJ, Gleeson N, Norris LA. Procoagulant activity in high grade serous ovarian cancer patients following neoadjuvant chemotherapy-The role of the activated protein C pathway. Thromb Res. 2021;200:91\u20138.","journal-title":"Thromb Res"},{"key":"3227_CR48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-019-0915-y","volume":"566","author":"BM Szczerba","year":"2019","unstructured":"Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, et al. Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566:553\u20137.","journal-title":"Nature"},{"key":"3227_CR49","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25189-z","volume":"12","author":"R Taftaf","year":"2021","unstructured":"Taftaf R, Liu X, Singh S, Jia Y, Dashzeveg NK, Hoffmann AD, et al. ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer. Nat Commun. 2021;12:4867.","journal-title":"Nat Commun"},{"key":"3227_CR50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.molmed.2013.03.005","volume":"19","author":"L Antonioli","year":"2013","unstructured":"Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013;19:355\u201367.","journal-title":"Trends Mol Med"},{"key":"3227_CR51","volume":"15","author":"CFF Gardani","year":"2024","unstructured":"Gardani CFF, Diz FM, Donde LB, Rockenbach L, Laufer S, Morrone FB. The potential role of purinergic signaling in cancer therapy: perspectives on anti-CD73 strategies for prostate cancer. Front Immunol. 2024;15:1455469.","journal-title":"Front Immunol"},{"key":"3227_CR52","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/s41416-024-02797-2","volume":"131","author":"MP Ward","year":"2024","unstructured":"Ward MP, O\u2019Toole SA, O\u2019Leary JJ. Potential role of the CD39-CD73 ATP-adenosine pathway in platelet mediated dissemination of circulating tumour cells. Br J Cancer. 2024;131:781\u20132.","journal-title":"Br J Cancer"},{"key":"3227_CR53","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/s41416-024-02640-8","volume":"130","author":"Z Ning","year":"2024","unstructured":"Ning Z, Liu K, Zhang H, Dong G, Wang X, Xiong H. Platelets induce CD39 expression in tumor cells to facilitate tumor metastasis. Br J Cancer. 2024;130:1542\u201351.","journal-title":"Br J Cancer"},{"key":"3227_CR54","volume":"10","author":"W Liu","year":"2023","unstructured":"Liu W, Yu X, Yuan Y, Feng Y, Wu C, Huang C, et al. CD73, a promising therapeutic target of diclofenac, promotes metastasis of pancreatic cancer through a nucleotidase independent mechanism. Adv Sci. 2023;10:e2206335.","journal-title":"Adv Sci"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03227-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03227-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03227-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T17:01:41Z","timestamp":1767459701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03227-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,31]]}},"alternative-id":["3227"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03227-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients included in this study give full and informed written consent (St. James\u2019 Hospital\/Tallaght University Hospital Joint Research Ethics Committee (Study ID:2095)). All healthy donor participants gave full and informed written consent, and the study had the approval of St. James\u2019s Hospital, and Adelaide and Meath Hospital, Dublin, incorporating the National Children\u2019s Hospital Research Ethics Committee (2012\/11\/04) and the Coombe Women & Infants University Hospital ethics committee. All methods were performed in accordance with the relevant guidelines and regulations of the Research Ethic Committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients before the use of their clinical materials for research purposes.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}